Dizal Pharmaceuticals
Clinical trials sponsored by Dizal Pharmaceuticals, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo offers hope for tough lung cancer Results expected Dec 2026 (estimated)
- Can a new pill boost chemotherapy against Hard-to-Treat lung cancer? Results expected Jun 2027 (estimated)
- New pill could help ITP patients who failed standard treatments Results expected Jul 2027 (estimated)
- New hope for blood cancer patients: experimental drug DZD8586 enters phase 2 trial Results expected Sep 2027 (estimated)
- New pill shows promise in early lung cancer trial Results expected Sep 2027 (estimated)
-
New pill could outperform chemo for rare lung cancer
Disease control OngoingThis phase 3 trial tests a new oral drug called sunvozertinib (DZD9008) against standard chemotherapy in 324 people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon20 insertion). Participants are randomly assigned to receive either the new drug or …
Phase 3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New pill shows promise against tough lung cancer
Disease control OngoingThis study tests a new daily pill, sunvozertinib (DZD9008), in people with advanced non-small cell lung cancer that has certain genetic mutations (EGFR or HER2) and has worsened after prior treatments. The trial aims to find safe doses and see if the drug can shrink tumors. About…
Phase 1/2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC